Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory

Neuropeptides

Volumn 32, Issue 5, 1998, Pages 417-421

  Raghavendra, V ^a   Chopra, K ^a   Kulkarni, S K ^a,b  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; PHYSOSTIGMINE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; SHORT TERM MEMORY; SPATIAL MEMORY;

ANIMALIA;

EID: 0031737223     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90065-8     Document Type: Article

References (27)

1. Bunneman B, Fuxe K, Ganten D. The renin-angiotensin system in the brain: an up date 1993. Regulatory Peptides 1993; 46: 487-509.
2. Wright J W, Harding J W. Brain angiotensin receptor subtypes in the control of physiological and behavioral response. Neuroscience and Biobehavioral Rev 1994; 18: 21-53.
3. Phillips M I. Functions of angiotensin in the central nervous system. Ann Rev Physiol 1987; 49: 413-435.
4. Wright J W, Harding J W. Regulatory role of brain angiotensin in the control of physiological and behavioral responses. Brain Research Rev 1992; 17: 227-262.
5. Jenkins T A, Allen A M, Chai S Y, Mendelsohn F A O. Interactions of angiotensin II with central catecholamines. Clin and Exper Hypertension 1995; 17: 267-280.
6. Raghavendra V, Chopra K, Kulkarni S K. Modulation of motor functions involving the dopaminergic system bt AT, receptor antagonist, losartan. Neuropeptides 1998; 32(3): 275-280.
7. 1 receptor. Peptides 1995; 16(6): 1069-1071.
8. Morgan T M, Routtenberg A. Angiotensin injected in to the neostriatum after learning disrupts retension performance. Science 1977; 196: 87-89.
9. DeNoble V J, DeNoble K F, Speneer K R et al. Timmermans B M. Non-peptide angiotensin II receptor antagonist and angiotensin converting enzyme inhibitor:effect on renin induced deficit of a passive avoidance response in rats. Brain Res 1991; 561: 230-235.
10. 1 receptors in hippocampal LTP. Pharmacol Biochem Behav 1993; 50: 259-264.
11. Mac Gregor D P, Murone C, Song K et al. Angiotensin II receptor subtypes in the human central nervous system. Brain Res 1995; 673: 231-240.
12. 1 receptor antagonist, losartan(DuP 753) on cognitive performance in the radial maze and in a delayed non-matching to position task in the rat. Br J Pharmacol 1992; 105: 88P.
13. Arrequi A, Perry K, Rossot M, Tomlmson B E. Angiotensin converting enzyme in Alzheimers disease. increased activity in caudate nucleus and cortical areas. J Neurol Chem. 1982; 39: 1490-1492.
14. Zubenko G S, Marquis J K, Volier I, Direnfeld I K. Cerebrospinal fluid levels of ACE, acetylcholinesterase and dopamine metabolites in dementia associated with Alzheimers disease and parkinosns disease a correlative study. Biol Psych 1986; 21: 1365-1381.
15. Costall B, Coughlan J, Horovitz Z P et al. The effect of ACE inhibitors captopril and SQ 29,852 in rodent tests of cognition. Pharmacol Biochem Behav 1989; 33: 573-574.
16. Mondadori C, Etienne P. Nootropic effects of ACE inhibitors in mice. Psychopharmacology 1990; 100: 301-307.
17. Stanhope K J, Mc Lenchan A P, Dourish C T. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology 1995; 122: 268-280.
18. Money E A, Kirk R C, Mc Naughton N. Alzheimers dementia produces a loss of discrimination but no increase in rate of memory decay in delayed matching to sample. Neuropsychologia 1992; 30: 133-143.
19. Sharma A C, Kulkarni S K. Evidence for GABA-BZ receptor modulation in short-term memory passive avoidance task paradigm in mice. Meth Find Clin Pharmacol 1990; 12(3): 175-180.
20. Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol 1991; 194: 71-76.
21. Sharma A C, Kulkarni S K. Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Prog Neuro-psychopharmacol and Biol-Psychiat 1992; 16: 117-125.
22. Barnes N M, Champaneria S, Costall B et al. Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. Neuroreport 1990; 1: 239-242.
23. Barnes N M, Champaneria S, Costall B et al. Anxiolytic like action of DuP 753, a non-peptide angiotensin II receptor antagonist. Neuroreport 1990; 1: 20-21.
24. Barnes J M, Barnes N M, Costall B et al. Angiotensin II inhibits acetyl choline release from human temporal cortex: implication for cognition. Brain Res 1990; 507: 341-343.
25. Barnes J M, Barnes N M, Costall B et al. Angiotensin II inhibits chortical cholinergic function: implication for cognition. J Cardiovascular Pharmacol 1990; 16: 234-238.
26. Rossor M. The neurochemistry of cortical dementias. In S M Stahl, S D Iversen and E C Godman (Eds.), Cognitive Neurochemistry, Oxford University Press. UK, 1987; 233-247.
27. Usinger P, Hock F J, Wiemer G et al. Hoe 288: indications on the memory enhancing effects of a peptidase inhibitor. Drug Dev Res 1988; 14: 325-324.